[HTML][HTML] Research progress on lung cancer stem cells in epidermal growth factor receptor–tyrosine kinase inhibitor targeted therapy resistance in lung …
H Zhang, Y Wang, X Yuan, Y Zou… - Oncology and …, 2024 - journals.lww.com
Lung cancer is the leading cause of cancer-related deaths globally. In recent years, with the
widespread use of genetic testing, epidermal growth factor receptor–tyrosine kinase inhibitor …
widespread use of genetic testing, epidermal growth factor receptor–tyrosine kinase inhibitor …
Recapitulating tumor microenvironment using preclinical 3D tissueoids model for accelerating cancer research and drug screening
A Baru, S Mazumdar, P Kundu, S Sharma… - BioRxiv, 2020 - biorxiv.org
The formation of three-dimensional spheroid tumor model using the scaffold-based
platforms has been demonstrated over many years now. 3D tumor models are generated …
platforms has been demonstrated over many years now. 3D tumor models are generated …
Emerging drugs for endometrial cancer
G Amadio, V Masciullo, MG Ferrandina… - Expert Opinion on …, 2014 - Taylor & Francis
Introduction: From the dualistic classification that divides endometrial cancer (EC) into two
types with distinct underlying molecular profiling, histopathology and clinical behavior …
types with distinct underlying molecular profiling, histopathology and clinical behavior …
Met activation and carcinogenesis
N Shinomiya, Q Xie, GF Vande Woude - Regulation of signal transduction …, 2018 - Springer
MET is a tyrosine kinase receptor that transduces intracellular signaling to activate the
MAPK, PI3K-Akt, and cadherin pathways (among others). In cancer cells, MET is activated …
MAPK, PI3K-Akt, and cadherin pathways (among others). In cancer cells, MET is activated …
Expression level of Wnt5a was related to the therapeutic effects of first-generation EGFR-TKIs
H Zhang, X Yang, F Hu, C Li, J Xu, W Nie… - OncoTargets and …, 2020 - Taylor & Francis
Background and Objective The first-generation epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs) have shown significant therapeutic effects on patients …
kinase inhibitors (EGFR-TKIs) have shown significant therapeutic effects on patients …
Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650
HAN Ruili, W Xiaoli, D Zhong, Z Juan… - Zhongguo Fei Ai …, 2012 - search.proquest.com
背景与目的 表皮生长因子受体 (epidermal growth factor receptor, EGFR) 高表达和突变与 40%
左右的肺癌有关, 已成为靶向治疗药物研究热点; 随着 Gefitinib 和 Erlotinib 作为 EGFR …
左右的肺癌有关, 已成为靶向治疗药物研究热点; 随着 Gefitinib 和 Erlotinib 作为 EGFR …
Personalized targeted therapy for lung cancer
K Wu, L House, W Liu, WCS Cho - Zhongguo Fei Ai Za Zhi, 2013 - search.proquest.com
由于每一肺癌患者在临床特征, 预后, 治疗反应和耐受性方面的进展都是独特的,
所以肺癌被认为是异质性疾病. 个体化用药是指运用标志物来预测哪些患者更易获益于某种治疗 …
所以肺癌被认为是异质性疾病. 个体化用药是指运用标志物来预测哪些患者更易获益于某种治疗 …
[HTML][HTML] 表皮生长因子受体突变细胞系H1650 耐药机制探讨
韩瑞丽， 王小丽， 钟殿胜， 赵娟， 陈哲… - Chinese Journal of …, 2012 - ncbi.nlm.nih.gov
背景与目的表皮生长因子受体(epidermal growth factor receptor, EGFR) 高表达和突变与40%
左右的肺癌有关, 已成为靶向治疗药物研究热点; 随着Gefitinib 和Erlotinib 作为EGFR …
左右的肺癌有关, 已成为靶向治疗药物研究热点; 随着Gefitinib 和Erlotinib 作为EGFR …
Τρέχουσες εξελίξεις στη μοντελοποίηση της ογκογένεσης του πνεύμονα με τη χρήση οργανοειδών που προέρχονται από ασθενείς
Μ Χωριανοπούλου - repo.lib.duth.gr
Lung cancer remains the most common cancer-related cause of death. Lung progenitor cells
are cells which apart from self-renewing, they have the capacity to generate other cell types …
are cells which apart from self-renewing, they have the capacity to generate other cell types …